Skip to content

Study · Non-randomized trial · 2002

7 results

A synthetic hexapeptide (Argireline) with antiwrinkle activity.

Blanes-Mira C, Clemente J, Jodas G, Gil A, Fernández-Ballester G, Ponsati B, Gutierrez L, Pérez-Payá E, Ferrer-Montiel A

International journal of cosmetic science1 Oct 2002Cited by 92 (Europe PMC)

PMID18498523 (opens in a new tab)DOI10.1046/j.1467-2494.2002.00153.x (opens in a new tab)PepBankPUB-18498523
Publisher pagePubMedAsk about this study
Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 1 result from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In healthy women, an emulsion containing Argireline reduced wrinkle depth by up to 30% after 30 days.

    In plain wordsIn healthy women, an Argireline emulsion reduced wrinkle depth by up to 30% after 30 days.

    Peptide
    Argireline (acetyl hexapeptide-8)
    Outcome
    DecreaseWrinkle depth
    Study

    n: not reported in source

    Outcome group
    Skin and hair · Skin and wound
    Studied dose
    10% · topical · 30 daysAs given in this study (human).

    Measurements

    Wrinkle depth reduction
    ≤ 30%
    after 30 days

    Source sentences

    Summary
    Noteworthy, skin topography analysis of an oil/water (O/W) emulsion containing 10% of the hexapeptide on healthy women volunteers reduced wrinkle depth up to 30% upon 30 days treatment.
  2. 02AnimalOther designSafety outcome

    In an unspecified in vivo model, Argireline did not exhibit oral toxicity at high doses.

    In plain wordsIn an unspecified animal model, Argireline showed no oral toxicity at high doses.

    Peptide
    Argireline (acetyl hexapeptide-8)
    Outcome
    No significant changeOral toxicity
    Study

    n: not reported in source

    Outcome group
    Adverse events · Whole body
    Studied dose
    high doses · oralAs given in this study.

    Source sentences

    Summary
    Notably, this peptide did not exhibit in vivo oral toxicity nor primary irritation at high doses.
  3. 03AnimalOther designSafety outcome

    In an unspecified in vivo model, Argireline did not exhibit primary irritation at high doses.

    In plain wordsIn an unspecified animal model, Argireline showed no primary irritation at high doses.

    Peptide
    Argireline (acetyl hexapeptide-8)
    Outcome
    No significant changePrimary irritation
    Study

    n: not reported in source

    Outcome group
    Adverse events · Skin and wound
    Studied dose
    high dosesAs given in this study.

    Source sentences

    Summary
    Notably, this peptide did not exhibit in vivo oral toxicity nor primary irritation at high doses.
  4. 04LabIn vitro (cells)Mechanism

    In laboratory tests, Argireline inhibited neurotransmitter release.

    In plain wordsIn lab tests, Argireline reduced neurotransmitter release.

    Peptide
    Argireline (acetyl hexapeptide-8)
    Outcome
    DecreaseNeurotransmitter release
    Study

    n: not reported in source

    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Analysis of the mechanism of action showed that Argireline significantly inhibited neurotransmitter release with a potency similar to that of BoNT A, although as expected, it displayed much lower efficacy than the neurotoxin.
  5. 05LabIn vitro (cells)Activity measurement

    In laboratory tests, Argireline inhibited neurotransmitter release with potency similar to BoNT A.

    In plain wordsIn lab tests, Argireline had similar potency to BoNT A for reducing neurotransmitter release.

    Peptide
    Argireline (acetyl hexapeptide-8)
    Outcome
    Not applicableNeurotransmitter release inhibition potency
    Study

    n: not reported in source

    Comparator
    BoNT A
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Analysis of the mechanism of action showed that Argireline significantly inhibited neurotransmitter release with a potency similar to that of BoNT A, although as expected, it displayed much lower efficacy than the neurotoxin.
  6. 06LabIn vitro (cells)Activity measurement

    In laboratory tests, Argireline had much lower neurotransmitter-release inhibition efficacy than BoNT A.

    In plain wordsIn lab tests, Argireline reduced neurotransmitter release less effectively than BoNT A.

    Peptide
    Argireline (acetyl hexapeptide-8)
    Outcome
    DecreaseNeurotransmitter release inhibition efficacy
    Study

    n: not reported in source

    Comparator
    BoNT A
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Analysis of the mechanism of action showed that Argireline significantly inhibited neurotransmitter release with a potency similar to that of BoNT A, although as expected, it displayed much lower efficacy than the neurotoxin.
  7. 07LabIn vitro (cells)Mechanism

    In laboratory tests, Argireline inhibited neurotransmitter release through interference with SNARE complex formation or stability.

    In plain wordsIn lab tests, Argireline interfered with formation or stability of the SNARE complex needed for neurotransmitter release.

    Peptide
    Argireline (acetyl hexapeptide-8)
    Outcome
    Not applicableSNARE complex formation or stability
    Study

    n: not reported in source

    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Inhibition of neurotransmitter release was due to the interference of the hexapeptide with the formation and/or stability of the protein complex that is required to drive Ca(2+)-dependent exocytosis, namely the vesicular fusion (known as SNARE) complex.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3NCT01381484

Argireline in Treatment of Periorbital Wrinkles

Mahidol Universityn = 70Mar 2009 to Sept 2009

Wrinkles

Trial pageClinicalTrials.govUpdated 27 Jun 2011

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:25 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.